Thomas M. Jahn

2.7k total citations · 1 hit paper
22 papers, 743 citations indexed

About

Thomas M. Jahn is a scholar working on Genetics, Pathology and Forensic Medicine and Immunology. According to data from OpenAlex, Thomas M. Jahn has authored 22 papers receiving a total of 743 indexed citations (citations by other indexed papers that have themselves been cited), including 19 papers in Genetics, 13 papers in Pathology and Forensic Medicine and 7 papers in Immunology. Recurrent topics in Thomas M. Jahn's work include Chronic Lymphocytic Leukemia Research (19 papers), Lymphoma Diagnosis and Treatment (13 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Thomas M. Jahn is often cited by papers focused on Chronic Lymphocytic Leukemia Research (19 papers), Lymphoma Diagnosis and Treatment (13 papers) and Immunodeficiency and Autoimmune Disorders (7 papers). Thomas M. Jahn collaborates with scholars based in United States, United Kingdom and Germany. Thomas M. Jahn's co-authors include Steven Coutré, Ian W. Flinn, Richard R. Furman, Nina D. Wagner‐Johnston, Brian J. Lannutti, Langdon L. Miller, Daniel Li, Jennifer R. Brown, Sissy Peterman and Brad S. Kahl and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Thomas M. Jahn

22 papers receiving 731 citations

Hit Papers

Idelalisib, an inhibitor of phosphatidylinositol 3-kinase... 2014 2026 2018 2022 2014 100 200 300 400
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
    2014 465 citations Jennifer R. Brown, John C. Byrd et al. Blood profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Thomas M. Jahn United States 11 636 437 236 219 204 22 743
Kerstin Allen United States 13 467 0.7× 472 1.1× 261 1.1× 248 1.1× 116 0.6× 18 754
Jennifer Orchard United Kingdom 12 590 0.9× 435 1.0× 99 0.4× 286 1.3× 145 0.7× 16 742
Yoonjin Cho United States 8 378 0.6× 327 0.7× 151 0.6× 98 0.4× 83 0.4× 16 480
Bertrand Anz United States 7 472 0.7× 391 0.9× 63 0.3× 168 0.8× 171 0.8× 20 543
Shih‐Shih Chen United States 12 321 0.5× 214 0.5× 126 0.5× 236 1.1× 76 0.4× 41 494
Sandra Robrecht Germany 12 415 0.7× 360 0.8× 72 0.3× 203 0.9× 98 0.5× 45 496
Antonia Rodríguez Spain 10 204 0.3× 284 0.6× 269 1.1× 99 0.5× 130 0.6× 14 595
Arnau Montraveta Spain 12 236 0.4× 182 0.4× 281 1.2× 96 0.4× 119 0.6× 17 492
Catriona Byrne United States 12 465 0.7× 251 0.6× 422 1.8× 100 0.5× 518 2.5× 35 807
Stefan Norin Sweden 9 216 0.3× 185 0.4× 127 0.5× 112 0.5× 78 0.4× 28 393

Countries citing papers authored by Thomas M. Jahn

Since Specialization
Citations

This map shows the geographic impact of Thomas M. Jahn's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Thomas M. Jahn with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Thomas M. Jahn more than expected).

Fields of papers citing papers by Thomas M. Jahn

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Thomas M. Jahn. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Thomas M. Jahn. The network helps show where Thomas M. Jahn may publish in the future.

Co-authorship network of co-authors of Thomas M. Jahn

This figure shows the co-authorship network connecting the top 25 collaborators of Thomas M. Jahn. A scholar is included among the top collaborators of Thomas M. Jahn based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Thomas M. Jahn. Thomas M. Jahn is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wainberg, Zev A., Yongjun Cha, Jasmaninder Singh Grewal, et al.. (2024). 659P Combination treatment with TTX-030, a first-in-class anti-CD39 antibody, in patients with advanced pancreatic cancer. Annals of Oncology. 35. S519–S520. 3 indexed citations
2.
Wainberg, Zev A., Yoon‐Koo Kang, Keun‐Wook Lee, et al.. (2022). Abstract CT015: Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the first line treatment of locally advanced or metastatic gastric/GEJ cancer. Cancer Research. 82(12_Supplement). CT015–CT015. 7 indexed citations
3.
Fong, Chun Yew, Andrew H. Wei, Mark G. Frattini, et al.. (2018). Phase 1b study of venetoclax in combination with azacitidine in patients with treatment-naïve higher-risk myelodysplastic syndromes.. Journal of Clinical Oncology. 36(15_suppl). TPS7082–TPS7082. 3 indexed citations
4.
Barrientos, Jacqueline C., Steven Coutré, Sven de Vos, et al.. (2015). Long-term follow-up of a phase Ib trial of idelalisib (IDELA) in combination with chemoimmunotherapy (CIT) in patients (pts) with relapsed/refractory (R/R) CLL including pts with del17p/TP53 mutation.. Journal of Clinical Oncology. 33(15_suppl). 7011–7011. 8 indexed citations
5.
Ghia, Paolo, Susan O’Brien, Peter Hillmen, et al.. (2014). Health-related quality of life (HRQL) impact of idelalisib (IDELA) in patients (pts) with relapsed chronic lymphocytic leukemia (CLL): Phase 3 results.. Journal of Clinical Oncology. 32(15_suppl). 7099–7099. 4 indexed citations
6.
7.
Coutré, Steven, Richard R. Furman, Jeff P. Sharman, et al.. (2014). Second interim analysis of a phase 3 study evaluating idelalisib and rituximab for relapsed CLL.. Journal of Clinical Oncology. 32(15_suppl). 7012–7012. 10 indexed citations
8.
9.
Sharman, Jeff P., Steven Coutré, Richard R. Furman, et al.. (2014). Efficacy of idelalisib in CLL subpopulations harboring del(17p) and other adverse prognostic factors: Results from a phase 3, randomized, double-blind, placebo-controlled trial.. Journal of Clinical Oncology. 32(15_suppl). 7011–7011. 8 indexed citations
10.
Brown, Jennifer R., John C. Byrd, Steven Coutré, et al.. (2014). Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia. Blood. 123(22). 3390–3397. 465 indexed citations breakdown →
11.
12.
13.
Eradat, Herbert, Steven Coutré, Jacqueline C. Barrientos, et al.. (2013). A phase III, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of idelalisib (GS-1101) in combination with bendamustine and rituximab for previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 31(15_suppl). TPS7133–TPS7133. 17 indexed citations
14.
Barrientos, Jacqueline C., Richard R. Furman, John P. Leonard, et al.. (2013). Update on a phase I study of the selective PI3Kδ inhibitor idelalisib (GS-1101) in combination with rituximab and/or bendamustine in patients with relapsed or refractory CLL.. Journal of Clinical Oncology. 31(15_suppl). 7017–7017. 31 indexed citations
15.
Brown, Jennifer R., Richard R. Furman, Ian W. Flinn, et al.. (2013). Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL.. Journal of Clinical Oncology. 31(15_suppl). 7003–7003. 37 indexed citations
16.
Furman, Richard R., Jacqueline C. Barrientos, Jeff P. Sharman, et al.. (2012). A phase I/II study of the selective phosphatidylinositol 3-kinase-delta (PI3Kδ) inhibitor, GS-1101 (CAL-101), with ofatumumab in patients with previously treated chronic lymphocytic leukemia (CLL).. Journal of Clinical Oncology. 30(15_suppl). 6518–6518. 21 indexed citations
17.
18.
19.
20.
Gündel, Harald, et al.. (2002). Erhöhte sympathische Grundaktivität bei hoch- versus niedrig-alexithymen Patienten mit spasmodischem Tortikollis. PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie. 52(11). 461–468. 7 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kerstin Allen Breakdown of academic impact, for papers by Jennifer Orchard Breakdown of academic impact, for papers by Yoonjin Cho Breakdown of academic impact, for papers by Bertrand Anz Breakdown of academic impact, for papers by Shih‐Shih Chen Breakdown of academic impact, for papers by Sandra Robrecht Breakdown of academic impact, for papers by Antonia Rodríguez Breakdown of academic impact, for papers by Arnau Montraveta Breakdown of academic impact, for papers by Catriona Byrne Breakdown of academic impact, for papers by Stefan Norin
Rankless by CCL
2026